Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.
about
The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus.Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
P2860
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adverse event burden, resource ...... systematic literature review.
@ast
Adverse event burden, resource ...... systematic literature review.
@en
type
label
Adverse event burden, resource ...... systematic literature review.
@ast
Adverse event burden, resource ...... systematic literature review.
@en
prefLabel
Adverse event burden, resource ...... systematic literature review.
@ast
Adverse event burden, resource ...... systematic literature review.
@en
P2093
P2860
P356
P1476
Adverse event burden, resource ...... systematic literature review.
@en
P2093
A Weinstein
C Paramore
S Narayanan
P2860
P304
P356
10.1155/2013/347520
P577
2013-04-03T00:00:00Z